Dr Lal PathLabs Limited announced on September 26, 2026, that its step-down subsidiary, Dr Lal PathLabs FZCO (DLPL Dubai), has completed the acquisition of an 80% stake in Sunshine Healthcare Limited (SHL) based in Ghana. This move solidifies the company's presence in the African diagnostic market.

The completion follows the earlier board approval by DLPL Dubai, a wholly owned subsidiary of Dr Lal PathLabs, which was intimated to stock exchanges on July 24, 2026. With this transaction finalized, SHL now operates as a step-down subsidiary of the Indian diagnostic chain.

Regulatory compliance and disclosures

The company stated that all mandatory disclosures required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, were duly completed. These disclosures were aligned with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, as amended from time to time.

The acquisition was executed in accordance with the agreement and prevailing provisions applicable in Ghana. Dr Lal PathLabs requested both the National Stock Exchange of India Limited and BSE Limited to take the completion details on record.

Strategic footprint expansion

This acquisition represents a significant step in Dr Lal PathLabs' international growth strategy, particularly within the West African region. By securing a majority stake in Sunshine Healthcare Limited, the company gains substantial control over local operations and market access.

The transaction highlights the company's continued focus on expanding its global diagnostic network through strategic acquisitions.

Dr. Lal Path Labs has acquired a 70% stake in SN Genelab Private Limited for up to ₹168 crore, with an additional performance-linked earn-out of up to ₹31.5 crore. The transaction, approved by the board on September 24, 2026, will make SN Gene a subsidiary of the company.

Deal structure and timeline

The acquisition involves a majority stake purchase from existing shareholders. The total consideration is structured as a primary cash payment of up to ₹168 crore and an earn-out component capped at ₹31.5 crore. The company stated that the transaction is expected to be completed by November 30, 2026. No governmental or regulatory approvals are required for the deal.

Strategic rationale and target profile

The primary objective of the acquisition is to strengthen Dr. Lal PathLabs' expertise in genomics and broaden its portfolio of advanced diagnostic services. SN Genelab Private Limited was incorporated on December 16, 2013, in Gujarat and operates in the diagnostics-genomics sector. The disclosure confirms that the proposed acquisition does not fall within the ambit of related party transactions.

Financials of the target entity

SN Genelab has shown consistent revenue growth over the last three fiscal years. The target's turnover increased from ₹43.27 crore in FY24 to ₹57.96 crore in FY26. This growth trajectory supports the strategic value of the acquisition for expanding the parent company's high-margin diagnostic capabilities.

What the numbers show

The acquisition price implies a significant premium relative to the target's current revenue base. With a primary consideration of ₹168 crore for a 70% stake, the implied enterprise value for 100% of SN Genelab exceeds ₹240 crore. Against FY26 turnover of ₹57.96 crore, this suggests a valuation multiple of approximately 4.1x revenue. The earn-out structure of up to ₹31.5 crore further aligns the seller's incentives with future performance, potentially raising the total cost to over ₹280 crore for full ownership if targets are met.